A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma

Inclusion Criteria: * Aged 18 to 80 on the day of signing the informed consent. * With a diagnosis of asthma for at least 6 months. * With pre-BD FEV1 ≥ 50% of the predicted value at the Screening visit (see section 18.6 for calculation of the predicted value for FEV1). * Having blood eosinophil counts ≥ 150 cells/μL at the Screening visit. * Participants who meet any of the following asthma criteria at the Screening visit: * Moderate asthma-1 (i.e., step 3 in asthma treatment steps in adults and adolescents from 2025 GINA guideline): * Moderate asthma-2 (i.e., step 4 in asthma treatment steps in adults and adolescents from 2025 GINA guideline): * Severe asthma (i.e., step 5 in asthma treatment steps in adults and adolescents from 2025 GINA guideline, except for biologic therapies): Exclusion Criteria: * A current smoker or quit smoking ≤ 0.5 years at Screening visit. * With serious underlying chronic illness or severe systemic disease, including but not limited to systemic lupus erythematosus, at the investigator's discretion. * With a current malignancy or previous history of cancer in remission for less than 5 years prior to Screening visit (Subject will not be excluded if he/she had localized carcinoma of the skin that was resected for cure). * With chronic heart failure in New York Heart Association class III to IV. * With clinically severe lung disease, including but not limited to cystic fibrosis, chronic bronchitis (chronic obstructive pulmonary disease othe…